… Gefitinib, erlotinib, and afatinib have comparable efficacies in terms of objective response …
-generation oral TKIs for T790M mutation; clinical trials if MET amplification, PIK3CA, BRAF, or …

… to our clinical experience with gefitinib. Our results should be seen as hypothesis generating,
in that docetaxel and erlotinib … needs testing in the context of randomised controlled trials. …

… the highest among published clinical trials without mandatory tumor sample collection and
the same as that in the Iressa Pan-Asia Study (IPASS) trial 19 that led to gefitinib registration (…

… Fukuoka JAPAN Research Institute for Diseases of The Chest, Kyushu University Hospital,
Fukuoka, JAPAN ABSTRACT Aim : A multicenter randomized phase III study designed to …

… At present, it is still controversial whether osimertinib can replace erlotinib or gefitinib as
the first-line treatment for patients with EGFR mutations. Therefore, the search for combination …

… safety findings with gefitinib. Overall survival, a secondary assessment, was not significantly
different between patients initially randomly assigned to either vandetanib or gefitinib. …

… reported in the earlier trials in which treatment with first-line gefitinib or erlotinib resulted
in superior ORR and DOR as compared to chemotherapy. [ 17 ] In clinical practice, ORR and …

… are the EGFR-tyrosine kinase inhibitors, such as gefitinib, erlotinib, or afatinib. Most of these
… a number of clinical studies have evaluated the combination of erlotinib with bevacizumab in …

… patients enrolled in the NCIC Clinical Trials Group phase III clinical trial BR21 (erlotinib vs.
placebo). Although it was not statistically significant, erlotinib-treated patients with statin use …

… Purpose: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus
… –small cell lung cancer (NSCLC) patients with acquired resistance to gefitinib or erlotinib. …